Burrows Scott L sold $126K of SYRE
Burrows Scott L (Chief Financial Officer) sold 1,801 shares of Spyre Therapeutics, Inc. (SYRE) at $69.75 ($0.13M total) on 2026-06-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The main tradable element is the disclosed sale (1,801 shares at $69.75) and the fact it was pre-planned, which typically lowers interpretive risk.
Market read
Provides a fresh insider-activity datapoint for SYRE, but lacks accompanying fundamental catalysts.
What to watch
Traders may over-weight insider sales; without concurrent news (trial, guidance, financing), the disclosure is more of a positioning signal than a fundamental one.
Background
SEC Form 4 reports an officer’s transaction in the issuer’s own stock; this one is an open-market sale executed under a pre-arranged Rule 10b5-1 plan.
Ticker impact
Spyre Therapeutics CFO Scott L. Burrows sold $125.6K of SYRE shares in an open-market transaction under a pre-arranged 10b5-1 plan.
Likely limited near-term impact; any reaction may be small and fade unless accompanied by other company-specific catalysts.
The filing provides a concrete datapoint (sale size/date/price) but no new operational or financial development; 10b5-1 typically dampens interpretive value.
Market effects
Minimal; this is company-specific insider activity with no stated sector-wide catalyst.
None indicated.
None indicated.
Counterpoint
Because the sale is under a pre-arranged 10b5-1 plan, it may reflect routine liquidity/compensation rather than bearish expectations.
Key entities
- issuerSpyre Therapeutics, Inc.
Subject of the insider transaction disclosure (SYRE).
- officerBurrows Scott L
CFO who sold shares under a 10b5-1 plan.
